Cyclic nucleotide elevating vasodilators inhibit platelet aggregation at an early step of the activation cascade.
The mechanism of vasodilator-induced inhibition of platelet aggregation was investigated in human platelets. Cyclic nucleotide-elevating vasodilators stimulated cAMP- or cGMP-dependent protein phosphorylation, inhibited the activation of both protein kinase C and myosin light chain kinase, and inhibited the thrombin-induced hydrolysis of phosphatidylinositol-4,5-bisphosphate without affecting its resynthesis. The results suggest that cAMP- and cGMP-elevating vasodilators both inhibit platelet aggregation at an early step of the activation cascade, presumably at the level of phospholipase C.
Waldmann
R
R
Labor für Klinische Biochemie, Medizinische Universitätsklinik, Würzburg, F.R.G.
Walter
U
U
D001798:Blood Proteins / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism*; D006801:Humans; D009599:Nitroprusside / Q000494:pharmacology; D010743:Phospholipids / Q000378:metabolism; D010766:Phosphorylation; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013917:Thrombin / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology*
D001798:Blood Proteins; D010743:Phospholipids; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D009599:Nitroprusside; D000242:Cyclic AMP; D013917:Thrombin; D006152:Cyclic GMP